Capricor Therapeutics Faces Class Action Lawsuit for Securities Violations Amid Controversial Drug Data Changes

Overview of Capricor Therapeutics, Inc. and the Lawsuit

On August 17, 2026, the DJS Law Group announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased shares of Capricor within the designated class period, from December 17, 2025, to July 26, 2026, are urged to take action.

Allegations

The complaint alleges that Capricor made false and misleading statements concerning the analysis of clinical data for its drug, Deramiocel. Specifically, the company reportedly altered the statistical analysis plan without securing the FDA's agreement before submitting a Biologics License Application for the drug. This significant oversight led to public statements from the company that were allegedly deceptive and materially misleading.

Class Action Details

As noted by DJS Law Group, shareholders who believe they have suffered losses due to Capricor's actions are encouraged to contact the firm for potential lead plaintiff appointments. Notably, being designated a lead plaintiff is not necessary to participate in any recovery.

The deadline for individuals to take action is September 28, 2026, making it essential for affected shareholders to seek legal counsel promptly.

DJS Law Group's Role

DJS Law Group specializes in enhancing investor returns through strategic counseling and vigorous advocacy. The firm is known for handling class action lawsuits and has represented a broad spectrum of clients, including some of the largest hedge funds and alternative asset managers globally. Their focus on securities litigation makes them a significant player in the legal landscape for investors.

Why This Matters to Investors

This situation underscores the importance of transparency and accountability in publicly traded companies. Investors rely on accurate and timely information to make informed decisions, and any discrepancies can have dire consequences on their financial interests. The allegations against Capricor raise concerns about the company's adherence to regulatory standards and might affect investor confidence.

Next Steps for Shareholders

If you purchased shares in Capricor during the class period and believe you may have been affected, now is the time to act. You should reach out to legal professionals to understand your options and the potential for recovery. The complexity of securities laws necessitates expert guidance, especially in light of the allegations against Capricor.

In conclusion, the class action lawsuit against Capricor Therapeutics serves as a pertinent reminder for investors about the risks involved in the market. Keeping informed and seeking legal assistance are critical steps in safeguarding one's investments against potential pitfalls.

For more information, feel free to contact: